Please ensure Javascript is enabled for purposes of website accessibility

Inovio Pharmaceuticals Announces Q4 Results, Stock Down 28%

By Mark Prvulovic - Mar 12, 2020 at 7:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This closely watched coronavirus stock just reported its financial figures.

Inovio Pharmaceuticals (INO -3.48%) has been one of the most volatile biotech stocks on the market as the company works on developing a potential COVID-19 coronavirus vaccine. After the markets closed on Thursday, Inovio released its fourth-quarter and 2019 full-year financial results.

As can be expected for an early-stage biotech stock, revenues were minimal overall, with the company reporting significant net losses. Total revenue came in at just $279,000 for the quarter, a significant decrease from the $2.5 million reported in Q4 2018. Inovio's net loss for the quarter came in at $37.7 million, which has slightly worsened from last year's $33 million net loss.

A vial labeled COVID-19 with a pipette in a laboratory.

Image source: Getty Images.

Inovio has a number of early-stage candidates undergoing development. Most notable is INO-4800, its promising COVID-19 treatment.

The biotech company had received a $9 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) earlier this year to develop a vaccine to counter the virus. Inovio also received a $5 million grant from the Bill and Melinda Gates Foundation to further test and scale a potential device that would allow the convenient delivery of the INO-4800 vaccine.

Further details

Shares of Inovio tumbled around 28% in after-hours trading on Thursday following the news. Although most Wall Street analysts covering the stock are bullish on the company's prospects, others have been more skeptical.

Notable short-seller Citron Research stated earlier this week that the U.S. Securities and Exchange Commission (SEC) should shut down Inovio and investigate claims made by the company. Inovio's stock fell by around 50% following the statement and has struggled to recover ever since.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.94 (-3.48%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.